New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice

Cancer Nursing

Volumn 22, Issue 3, 1999, Pages 212-219

  Stucky Marshall, Lisa ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Colorectal carcinoma; Irinotecan; Late diarrhea

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; HEALTH CARE PERSONNEL; HUMAN; METASTASIS; OUTPATIENT CARE; PANCREAS CANCER; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; ONCOLOGIC NURSING; PANCREATIC NEOPLASMS;

EID: 0032856597     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-199906000-00004     Document Type: Article

References (22)

1. Landis, SH, Taylor, M, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapynaive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
3. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
4. Burris III HA, Fields SM. Topoisomerase I inhibitors: an overview of the camptothecin analogs. New Drug Ther 1994;8:333-55.
5. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995;49:11-19.
6. Liu LF. Topoisomerase I - targeting drugs: mechanisms of inhibition and cytotoxicity. In: Taguchi T, Wang JC, eds. 5th World Conference on Clinical Pharmacology Therapeutics: highlights of a satellite symposium: approaches to cancer treatment by topoisomerase I inhibitors. Tokyo: BIOMEDIS, 1992:6-9.
7. Creemers GJ, Lund B, Verweij J. New drugs: topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20: 73-96.
8. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in patients with metastatic colorectal cancer. J Clin Oncol 1993;11:909-13.
9. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
10. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
11. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin in Oncol 1996;23: 34-41.
12. CAMPTOSAR brand of irinotecan hydrochloride injection. In: Arky R, ed. Physician's desk reference. Montvale, NJ: Medical Economics Data Production Company. 1997:2060-4.
13. Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin Oncol 1996;23:42-50.
14. Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) Study. Proceedings of the American Society of Clinical Oncology 1994:13. [abstract 573]
15. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
16. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996;23:21-6.
17. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:427-36.
18. Gandia D, Abigerges D, Armand JP, Chabot GG, DaCosta L, DeForni M. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993;11:196-7.
19. Abigerges D, Armand J-P, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
20. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
21. Takeuchi S, Noda K, Yakushiji M, and CPT-11 Study Group on Gynecologic Malignancy. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC). Proc Am Soc Clin Oncol 1992;11. [abstract 708]
22. Wagener DJT, Verdonk HER, Dirix LL, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer: an EORTC early clinical trials group study. Ann Oncol 1995;6:129-32.